How Prescription Medications Can Impair Driving Ability

Medication safety is not limited to achieving the intended therapeutic effect. In 2024, the US Food and Drug Administration (FDA) published an article titled ‘Some Medicines and Driving Don’t Mix,’ and there is much truth to that.

Many prescription medications can affect alertness, reaction time, coordination, and other functions essential to driving. According to a 2025 randomized controlled trial, simulated driving impairment persisted for up to 12.5 hours after a nighttime 2-mg dose of alprazolam. The same lasted up to 8.5 hours after a nighttime 10-mg dose of zolpidem.

What’s interesting is that participants in the trial did not recognize their degree of impairment. On that note, medication-related driving impairment sits at the intersection of pharmacology, labeling, prescription, and patient counseling.

This article will explore how prescription medications can impair driving ability in detail. The considerations discussed here will provide a clearer framework for pharmaceutical and healthcare professionals to understand and communicate medication-related driving risks.

What Makes a Prescription Medication Unsafe When You Are Behind the Wheel?

If a prescription medication has the potential to interfere with a driver’s ability to operate a vehicle safely, it becomes a driving safety concern. This concern is not limited to drowsiness. Impairment also means reduced alertness, difficulty in concentrating, and poor judgment.

Certain medications can produce such effects even when they are taken as directed. Pharmaceutical professionals must remember that a medication does not have to make someone sedated to affect driving performance. In many cases, the effects are so subtle that an individual is not immediately able to realize that their faculties are affected.

Here are the common medication-related effects that can make driving not only difficult, but highly dangerous:

• Sleepiness that makes it difficult to maintain attention on the road and surroundings
• Delayed reaction time that affects how quickly a driver changes direction or responds to an unexpected hazard
• Impaired coordination that interferes with steering, braking, and other actions requiring precise movement
• Dizziness that compromises a driver’s ability to maintain control of the vehicle
• Blurred vision that makes it challenging to identify hazards and accurately judge distances between vehicles
• Confusion that impacts decision-making behind the wheel

These effects become especially consequential when an impaired driver gets behind the wheel and causes a collision. Depending on the circumstances, other road users may suffer serious consequences, including concussions and traumatic brain injuries.

The fact that a medication was legally prescribed does not remove responsibility for negligence while driving. Loewy Law Firm shares that negligence is the cornerstone of traumatic brain injury cases. It means what needs to be proved is that the at-fault party owed a duty of care, breached that duty, and the breach caused the injury.

All of the above rings true of a driver crashing their vehicle in their medication-induced impaired state. This means they may face allegations of negligence. A driver impaired by a prescription is still a negligent driver, and brain injury laws will determine what an injured victim can claim and the time limits for filing a claim. Pharmacists who understand these risks have an important foundation for medication counseling.

Which Prescription Medications Can Affect Driving?

The risk to driving ability is particularly prevalent among medicines that act on the central nervous system. Still, the extent of impairment varies by dosage, formulation, treatment duration, and patient response.

Some medications cause impairment primarily after initiation or dose increase, while others produce residual effects that extend into the following day. Let’s look at the medication classes that warrant close attention for driving-related risks:

Sleep Aids

This class of prescription medications is designed to promote sleep, but its sedative effects may move way beyond the intended sleeping hours. Depending on the dose, residual effects may include drowsiness, slower reaction time, and difficulty maintaining attention.

Long-acting agents or medications taken late at night are especially relevant here. The zolpidem mentioned previously in the intro is a good example. Clearly, the impairment lasted a long time (8.5 hours), especially since many people do not sleep 7-9 hours each night.

Benzodiazepines

These prescription medications, used to enhance the activity of gamma-aminobutyric acid (GABA), can produce sedation, muscle relaxation, and reduced anxiety. The same effects can interfere with driving-related functions, including attention, psychomotor coordination, and judgment.

A 2024 scoping review examined 183 studies covering 20 benzodiazepine receptor agonists. 78 out of 92 experimental studies (85%) identified impairment in at least one measure of driving performance. The researchers concluded that driving performance is affected, and that effects may vary by medication and testing method.

Opioids

Despite being used for pain management, opioids can affect the central nervous system. The resulting drowsiness, slower cognitive processing, and reduced alertness may impact a driver’s ability to respond to hazards on the road.

This risk is especially important when opioid therapy is newly initiated, the dosage is increased, or another sedative medication is introduced. In a 2026 narrative review that examined 38 epidemiological studies and 21 psychomotor studies, the conclusion was mixed.

In other words, some studies demonstrated impairment due to opioids, whereas others showed minimal effects. Initiation of the therapy and combinations with other psychoactive medications were the determining factors.

Muscle Relaxers

Many muscle relaxers can slow the central nervous system. Depending on the specific medicine, an individual may experience dizziness, weakness, blurred vision, or a lack of coordination.

These effects are most evident when one performs tasks requiring utmost attention and rapid physical responses. Since muscle relaxers differ considerably in their pharmacologic profiles, driving-related counseling should be based on the specific medication.

Certain Antihistamines

In particular, first-generation antihistamines can cross the blood-brain barrier and cause sedation and slower reaction times. Such effects may occur even when the medication is being used for a common allergy.

With second-generation antihistamines, individual medications and patient responses differ. In a 2025 study, researchers examined 319 blood specimens from impaired driving investigations that tested positive for hydroxyzine. Reported observations included slurred speech, difficulty following instructions, and running stop signs.

Anti-Seizure Medicines

Some medications prescribed for seizures can also produce sedative effects that impair driving. A 2024 review of commonly prescribed anti-seizure medications found that acute administration of carbamazepine impaired driving performance, while chronic monotherapy with the same medication, along with others, did not produce the same effects.

This makes the treatment stage particularly relevant. The driving-related effects can be seen when therapy is first initiated or when the dosage is changed. Driving guidance for patients taking anti-seizure medications depends on the specific medicine, treatment regimen, and clinical response.

What Does a Driving Warning on a Prescription Label Mean?

If there is a driving warning found on a prescription medication label, it’s not a general caution about feeling sleepy. What the label is trying to communicate is that the medicine can affect functions necessary for safe driving. This means reaction time, alertness, coordination, vision, and judgment may be affected.

The significance of the warning depends on the medication’s pharmacologic profile, dose, formulation, timing, and the patient’s response. The wording on the labeling may help understand the nature of the precaution. For instance, ‘may cause drowsiness’ means sedation is a possible side effect.

Yet, it does not mean every patient will experience the same degree of impairment. On the other hand, ‘do not drive or operate machinery’ is a more direct precaution based on the medication’s known or anticipated effects. For a thorough risk assessment, pharmacists and healthcare professionals consider factors that can modify both the severity and duration of impairment, including:

• Dose and formulation, since higher doses and extended-release formulations can produce different exposure patterns
• Timing, since a medication taken at night can still affect driving performance the next morning
• Treatment changes, as starting a new therapy or increasing dosage can produce effects different from those experienced during established treatment
• Alcohol and other substances, as concurrent use can intensify sedative effects
• Patient-specific factors, such as age, metabolism, organ function, and individual sensitivity

In May 2026, a Florida judge authorized prosecutors to obtain Tiger Woods’ prescription medication records after his March crash and DUI arrest. Authorities reported finding two pain pills in his possession and observing signs of impairment. The Breathalyzer showed no signs of alcohol.

Unlike alcohol, Florida had no clear threshold for impairment from medications, making evidence such as field sobriety observations, officer testimony, and medication records relevant to the investigation. Woods has pleaded not guilty.

For pharmaceutical professionals, this case does not establish that a prescription medication caused Woods’ impairment. Instead, it highlights the importance of medication-specific information in driving impairment cases. Hence, a prescription label needs to be understood as the starting point for risk communication.

How Long Can Medication-Related Impairment Last?

Medication-related impairment does not end when a patient stops feeling sleepy or sedated. Based on the medication’s properties and the patient’s response, effects on attention and coordination may continue.

Pharmacists and healthcare professionals need to consider this because how a patient feels is not always a reliable sign of whether driving performance has returned to baseline. Scott Youngquist, MD, an emergency medicine physician at University of Utah Health, clearly noted, “People taking these medications may not feel adverse effects, even though their reaction time is slowed.”

On that note, the duration of a medicine’s sedative effects can be understood through the following practical patterns:

• Half-life: A medicine with a longer elimination half-life generally remains in the body for a longer duration, thereby increasing the potential for residual effects.
• Active metabolites: Some medications are converted into metabolites that remain pharmacologically active, which can extend the residual effects beyond that of the parent medicine.
• Accumulation with repeated dosing: When doses are taken before the previous dose has been fully eliminated, medication concentrations in the body build up, contributing to more persistent effects.
• Medication effect versus its concentration: The amount of medication remaining in the body does not always correspond to how impaired someone feels. Driving-related effects can sometimes continue even as medication levels decline.

For this reason, medicine-related impairment cannot be assigned a universal ‘safe after X hours’ rule. A short-acting medicine may have relatively limited residual effects. On the other hand, a longer-acting medicine or one with active metabolites may continue affecting performance much later.

Where Does Pharmacist Counseling About Driving Risks Tend to Stop?

Pharmacists who understand medication-related driving risks can make counseling much more useful. They can explain the relevant impairment, review the complete medication profile, and discuss when the effects may matter the most.

While that’s important, a standard dispensing conversation may not involve how those risks evolve throughout treatment. A warning at the point of dispensing may explain that a medicine can cause drowsiness or impair driving, yet what about the time the patient’s medication regimen changes?

A 2024 JAMA Network Open cohort study examined 154,096 crashes involving 121,846 older drivers. It found that 80% of crashes involved use of at least one medication with the potential for driving impairment in the 120 days before the crash. 81% involved such medication use in the 120 days afterward.

Researchers concluded that most older drivers involved in crashes did not use fewer potentially driver-impairing medications afterward. This does not imply that the medications were the direct cause of the crashes. However, it does highlight that a crash does not necessarily reduce exposure to medications that may affect driving.

This raises the question of whether driving risk should be reconsidered when treatment continues or changes. Routine counseling mostly addresses only the immediate warning. More detailed assessment also calls for attention to:

• Continuation of therapy: A driving precaution given when the medication is first dispensed may not automatically be reassessed during subsequent refills.
• Changes after a clinical event: A crash, fall, hospitalization, or other event may create a reason to reevaluate medications with sedative effects.
• The overall medication regimen: Driving implications of several medications may be different from those of an individual prescription considered in isolation.
• Communication across care settings: Medication changes made by prescribing physicians may not always lead to a renewed discussion at the pharmacy counter unless the issue is specifically identified.

In practice, pharmacist counseling about driving risks tends to stop at communicating the medication’s warning and providing initial guidance. However, the clinical situation may call for a more individualized medication safety discussion as mentioned above.

FAQs

Which prescription medications should pharmacists flag for potential driving impairment?

Pharmacists should pay close attention to medications that impact the central nervous system (CNS). These may include sleep aids, opioids, benzodiazepines, muscle relaxers, certain antihistamines, and anti-seizure medications. Risk may vary by dosage, formulation, treatment stage, and patient response.

How can pharmacists determine how long a medication may affect driving ability?

Pharmacists should consider the medication’s half-life, active metabolites, dosing schedule, formulation, and patient-specific factors. Impairment may persist after sedation subsides, so one must not rely on how alert patients feel to determine whether driving is safe.

When should pharmacists reassess a patient’s driving-related medication risks?

Reassessment is particularly important while starting or increasing a medication dose, changing formulations, or after a fall or crash. Reviewing the complete medication regimen can also identify combined effects that may not be apparent when prescriptions are viewed individually.

Key Considerations for Medication-Related Risks

Finally, the practical responsibility of a pharmacist is not to determine whether every patient is fit to drive. It is to recognize when and how a medication creates a meaningful driving-related concern.

New therapies, changes in treatment, adverse effects, and significant safety events can all provide opportunities to reassess the risk and communicate it effectively. Also, as discussed, questions of negligence don’t disappear just because a driver was impaired by a prescription medication.

Understanding these connections allows pharmaceutical professionals to view driving warnings as more than labeling language. That’s because they are an important part of responsible medication use, with implications for public safety.